Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ALEC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ALEC

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Alector Inc

ALEC
Current price
1.61 USD -0.08 USD (-4.73%)
Last closed 1.72 USD
ISIN US0144421072
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 171 987 280 USD
Yield for 12 month -71.90 %
1Y
3Y
5Y
10Y
15Y
ALEC
21.11.2021 - 28.11.2021

Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California. Address: 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.65 USD

P/E Ratio

Dividend Yield

Financials ALEC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ALEC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+100 558 000 USD

Last Year

+97 062 000 USD

Current Quarter

+3 674 000 USD

Last Quarter

+54 240 000 USD

Current Year

+91 717 000 USD

Last Year

-95 053 000 USD

Current Quarter

+3 674 000 USD

Last Quarter

+52 162 000 USD
EBITDA -138 831 008 USD
Operating Margin TTM -1 216.52 %
Price to Earnings
Return On Assets TTM -17.22 %
PEG Ratio
Return On Equity TTM -90.26 %
Wall Street Target Price 4.65 USD
Revenue TTM 88 339 000 USD
Book Value 0.95 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -76.90 %
Dividend Yield
Gross Profit TTM -86 075 000 USD
Earnings per share -1.26 USD
Diluted Eps TTM -1.26 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -86.30 %
Profit Margin -139.74 %

Stock Valuation ALEC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 526.32
Enterprise Value Revenue 2.38
Price Sales TTM 1.95
Enterprise Value EBITDA -8.40
Price Book MRQ 1.74

Technical Indicators ALEC

For 52 Weeks

0.87 USD 6.78 USD
50 Day MA 1.37 USD
Shares Short Prior Month 6 372 729
200 Day MA 2.31 USD
Short Ratio 6.32
Shares Short 6 180 489
Short Percent 8.06 %